MA48480A - Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin - Google Patents

Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Info

Publication number
MA48480A
MA48480A MA048480A MA48480A MA48480A MA 48480 A MA48480 A MA 48480A MA 048480 A MA048480 A MA 048480A MA 48480 A MA48480 A MA 48480A MA 48480 A MA48480 A MA 48480A
Authority
MA
Morocco
Prior art keywords
blood plasma
cognitive
treatment
dosage schedule
products
Prior art date
Application number
MA048480A
Other languages
English (en)
Inventor
Steven P Braithwaite
Eva Czirr
Ian Gallager
Nina Huber
S Sakura Minami
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MA48480A publication Critical patent/MA48480A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
MA048480A 2017-04-26 2018-04-24 Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin MA48480A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762490519P 2017-04-26 2017-04-26
US201762584571P 2017-11-10 2017-11-10
US201862623468P 2018-01-29 2018-01-29
US201862641194P 2018-03-09 2018-03-09

Publications (1)

Publication Number Publication Date
MA48480A true MA48480A (fr) 2020-03-04

Family

ID=63915938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048480A MA48480A (fr) 2017-04-26 2018-04-24 Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Country Status (20)

Country Link
US (3) US10357513B2 (fr)
EP (2) EP4299129A3 (fr)
JP (2) JP2020517693A (fr)
KR (1) KR20190135059A (fr)
CN (2) CN117899111A (fr)
AU (1) AU2018257921B2 (fr)
BR (1) BR112019022402A2 (fr)
CA (1) CA3061194A1 (fr)
CL (1) CL2019003076A1 (fr)
CO (1) CO2019012385A2 (fr)
DK (1) DK3615057T3 (fr)
ES (1) ES2971462T3 (fr)
IL (2) IL305904A (fr)
MA (1) MA48480A (fr)
MX (1) MX2019012795A (fr)
SG (1) SG11201909927RA (fr)
TW (2) TW202332455A (fr)
UA (1) UA127828C2 (fr)
WO (1) WO2018200560A1 (fr)
ZA (1) ZA202301009B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973431B2 (en) * 2014-02-14 2021-04-13 Beth Israel Deaconess Medical Center, Inc. Electrical impedance myography
UA126232C2 (uk) * 2016-08-18 2022-09-07 Алкахест, Інк. Спосіб лікування когнітивного розладу, пов'язаного зі старінням, та набір, що містить фракцію плазми крові
CA3061194A1 (fr) 2017-04-26 2018-11-01 Alkahest, Inc. Schema posologique pour le traitement de deficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
MX2020011114A (es) 2018-05-15 2021-01-29 Alkahest Inc Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
WO2020018343A1 (fr) * 2018-07-20 2020-01-23 Alkahest, Inc. Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin
AU2019364271A1 (en) * 2018-10-26 2021-06-03 Alkahest, Inc. Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
GB201904810D0 (en) 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
CN114727761A (zh) * 2019-09-17 2022-07-08 豪夫迈·罗氏有限公司 患有运动障碍的患者的个性化保健的改善
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
WO2021102032A1 (fr) 2019-11-20 2021-05-27 Alkahest, Inc. Fractions de plasma sanguin destinées à être utilisées dans la régénération du foie
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
EP4216225A1 (fr) * 2022-01-20 2023-07-26 Koninklijke Philips N.V. Appareil de détermination de la déficience cognitive
US20240033279A1 (en) * 2022-07-06 2024-02-01 Yuvan Research, Inc. Rna-enriched anti-aging compositions and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20040120937A1 (en) 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
EP1608374B9 (fr) 2003-03-24 2009-04-08 Axikin Pharmaceuticals, Inc. Derives de 2-phenoxy- et 2-phenylsulfonamide a activite antagoniste de ccr3 pour le traitement de l'asthme et d'autres troubles inflammatoires ou immunologiques
WO2004093802A2 (fr) 2003-04-17 2004-11-04 The Board Of Trustees Of The Leland Stanford Junior University Prevention des troubles de neurogenese deficitaire a l'aide d'agents anti-inflammatoires
PT2211183E (pt) 2003-11-19 2013-05-31 Satoris Inc Método para diagnosticar e monitorizar a doença de alzheimer
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
WO2005106492A2 (fr) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US20090181008A1 (en) 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
EP2008100A4 (fr) 2006-04-18 2009-12-16 Univ Leland Stanford Junior Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
BRPI0815551A2 (pt) 2007-08-15 2015-02-18 Univ South Florida Tratamento através de hucbc de doença beta-amiloide
US8097645B2 (en) 2007-10-12 2012-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compounds for activating TGF-β signaling
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
US9616393B2 (en) 2007-12-06 2017-04-11 Asahi Kasei Medical Co., Ltd. Porous hollow fiber membrane for treating blood
AU2009236305B2 (en) 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
WO2009155069A1 (fr) * 2008-05-28 2009-12-23 Allan Mishra Compositions et procédés pour traiter des troubles psychiatriques et neurodégénératifs
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
WO2017120461A1 (fr) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Modulation du ccr3 pour le traitement de déficiences associées au vieillissement, et compositions utilisées pour cette modulation
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20130040844A1 (en) 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP6008842B2 (ja) 2010-05-04 2016-10-19 ファイブ プライム セラピューティックス インコーポレイテッド Ｃｓｆ１ｒに結合する抗体
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
US20150079045A1 (en) 2012-02-13 2015-03-19 Wuyi Kong Nprcps, pfdncs and uses thereof
WO2013142135A1 (fr) 2012-03-20 2013-09-26 Albert Einstein College Of Medicine Of Yeshiva University Procédé d'amélioration de l'efficacité de transfusions sanguines
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013184646A2 (fr) * 2012-06-05 2013-12-12 Synagile Corporation Posologies pour les compositions acides destinées à être perfusées par voie sous-cutanée
RU2635560C2 (ru) 2012-10-29 2017-11-14 Чайна Петролеум Энд Кемикал Корпорейшн Способ адсорбционной десульфуризации углеводородов и реакторное устройство для его осуществления
ES2740127T3 (es) * 2013-05-06 2020-02-05 Baxalta Inc Tratamiento de subpoblaciones con enfermedad de Alzheimer con inmunoglobulina G combinada
US20150061767A1 (en) 2013-08-28 2015-03-05 Texas Instruments Incorporated Telescopic Amplifier with Improved Common Mode Settling
WO2015088915A1 (fr) * 2013-12-09 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et compositions pour traiter des états associés au vieillissement
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
KR20180030965A (ko) 2015-05-18 2018-03-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화 관련 장애를 치료하기 위한 방법 및 조성물
KR102240347B1 (ko) 2015-06-15 2021-04-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
US11628190B2 (en) * 2015-08-28 2023-04-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
UA126232C2 (uk) * 2016-08-18 2022-09-07 Алкахест, Інк. Спосіб лікування когнітивного розладу, пов'язаного зі старінням, та набір, що містить фракцію плазми крові
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CA3061194A1 (fr) 2017-04-26 2018-11-01 Alkahest, Inc. Schema posologique pour le traitement de deficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Also Published As

Publication number Publication date
IL270125B1 (en) 2023-10-01
US11413308B2 (en) 2022-08-16
UA127828C2 (uk) 2024-01-17
TW201841646A (zh) 2018-12-01
CO2019012385A2 (es) 2020-01-17
CL2019003076A1 (es) 2020-01-31
MX2019012795A (es) 2020-02-13
US20180311280A1 (en) 2018-11-01
CN110709098A (zh) 2020-01-17
AU2018257921A1 (en) 2019-11-14
EP3615057A1 (fr) 2020-03-04
WO2018200560A1 (fr) 2018-11-01
US10357513B2 (en) 2019-07-23
TWI782009B (zh) 2022-11-01
NZ758615A (en) 2023-09-29
AU2018257921B2 (en) 2024-06-06
US10874692B2 (en) 2020-12-29
KR20190135059A (ko) 2019-12-05
IL305904A (en) 2023-11-01
DK3615057T3 (da) 2024-01-02
CN117899111A (zh) 2024-04-19
EP4299129A3 (fr) 2024-03-20
US20210060063A1 (en) 2021-03-04
US20190282617A1 (en) 2019-09-19
ES2971462T3 (es) 2024-06-05
BR112019022402A2 (pt) 2020-05-19
IL270125A (fr) 2019-12-31
ZA202301009B (en) 2023-10-25
IL270125B2 (en) 2024-02-01
JP2020517693A (ja) 2020-06-18
SG11201909927RA (en) 2019-11-28
CN110709098B (zh) 2024-01-30
EP3615057A4 (fr) 2020-09-30
TW202332455A (zh) 2023-08-16
EP3615057B1 (fr) 2023-11-29
JP2023036856A (ja) 2023-03-14
EP4299129A2 (fr) 2024-01-03
CA3061194A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
MA48480A (fr) Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
MA53182A (fr) Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL254030B (en) Use of pyridofidine to improve cognitive function and to treat Alzheimer's disease
HK1253769A1 (zh) 用於診斷和治療腎上腺腦白質營養不良的方法和組合物
HK1259031A1 (zh) 使用治療有效量的活化脂肪酸預防、治療和逆轉疾病
MA41299A (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
HK1247963A1 (zh) 用於hiv的治療的基因療法及其用途
PT3334693T (pt) Processo e sistema para o tratamento contínuo de águas residuais.
IL291642A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
HK1257236A1 (zh) 預防和治療高脂血症的藥物及其用途
SG11201706471QA (en) Treatment and resourcelization of acid waste gas
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EP3518668A4 (fr) Diagnostic de prédisposition génétique et traitement de troubles mentaux
FR3020951B1 (fr) Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique.
EP3723742C0 (fr) Utilisation de la fluoroethylnormemantine pour la prevention et le traitement de l'anxiete
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
MA41090A (fr) Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
MA41142A (fr) Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement